ImmunityBio
Open
$7.14
Prev. Close
$7.14
High
$7.14
Low
$7.10
Market Snapshot
$7.3B
-8.5
-0.59
$14.75M
688
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Recently from Cashu
ImmunityBio Partners with BCG Laboratory to Enhance Bladder Cancer Treatment Supply and Options
ImmunityBio has secured a critical partnership with Japan's BCG Laboratory to enhance the supply of Bacillus Calmette-Guérin (BCG) in the United States, addressing an urgent need in the treatment of b…
ImmunityBio Partners with BCG Laboratory to Address Bladder Cancer Treatment Shortages
ImmunityBio's recent partnership with Japan's BCG Laboratory represents a vital step in addressing the ongoing shortages of Bacillus Calmette-Guérin (BCG) used in bladder cancer treatments. This agree…
ImmunityBio Secures $75 Million Amid Class Action Lawsuits and FDA Warning on Anktiva Claims
ImmunityBio Strengthens Financial Foundation Amid Class Action Lawsuits ImmunityBio has successfully secured $75 million in non-dilutive financing through a strategic deal with Oberland Capital. This…
ImmunityBio’s Anktiva Approved for BCG-Unresponsive Bladder Cancer Treatment, Transforming Patient Care
ImmunityBio's Breakthrough in Bladder Cancer Treatment ImmunityBio recently celebrates a significant development in oncology with the approval of its immunotherapy drug, Anktiva, in combination with B…